Martini Gregory S. 4

What Happened

• Gregory S. Martini, Chief Financial Officer of Ironwood Pharmaceuticals (IRWD), received a grant of 136,612 restricted stock units (RSUs) on March 10, 2026. The Form 4 reports an acquisition price of $0.00 (transaction coded as A — award/grant). The filing lists the grant as an annual performance award; no cash value is shown in the filing excerpt.

Key Details

• Transaction date: 2026-03-10; Form 4 filed: 2026-03-12.
• Shares/units granted: 136,612 RSUs; reported acquisition price: $0.00.
• Vesting: Award vests 25% on each approximate anniversary of the grant (per footnote — typical four-year pro rata vesting).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The RSU is an annual performance award with the 25% per-year vesting schedule.
• Filing timeliness: Form 4 was filed two days after the reported grant (no late-filing flag shown in the excerpt).

Context

• RSU grants are compensation awards, not open-market purchases or sales. These awards typically convert to actual shares only as they vest and may be subject to company plan terms and tax withholding. Because this is a compensation grant tied to service/performance, it should be viewed as part of executive pay rather than a direct bullish or bearish market signal.